Conversely, A-TPO prevalence decreased in multiple tumor types receiving immuno-therapy, including gastrointestinal tumors, hepatocellular carcinoma, breast cancer, lymphoma, and melanoma. This evidence concerns the gene TPO and hepatocellular carcinoma.